2.18.25 -GSK Expands Meningitis Vaccine Offerings with New FDA Approved 5-in-1 Meningococcal Vaccine
The FDA approved the British drugmaker’s Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A, B, C, W and Y (MenABCWY), which together cause the most invasive meningococcal disease (IMD) cases globally. The shot mixes the antigenic components of GSK’s established meningococcal vaccines Bexsero and Menveo, which target MenB and MenACWY, respectively, to offer broader coverage in fewer doses.
Access Vaccines members receive discounted member pricing on both GSK and Pfizer’s 5-in-1 Meningococcal vaccines. Join Access Vaccines today to save on all your meningococcal purchases.
2.5.25 – 2025/26 Flu Prebook is Now Open
The prebook period for Access Vaccines members for the 2025/26 flu season has officially started. Now is the time to reserve your doses. Access Vaccines members have the choice between all brands of flu, at the lowest national prices for each brand:
Seqirus:
Flucelvax (6+ months) *cell-based
– Afluria (6+ months)
– FluAd (65+ years)
Sanofi:
– Fluzone (6+ months)
– Flublok (18+ years)
– Fluzone High Dose (65+ years)
GSK:
– FluLaval (6+ months)
– Fluarix (6+months)
AstraZeneca:
– FluMist (2-49 years)
1.27.25 – CDC Update: ACIP Recommended Adult Immunizations: Highlighting Pneumococcal
The ACIP has published its updated recommendations for Adult Immunizations. Including in its recommendations, the newest adult pneumococcal vaccine covering 21 conjugates: Capvaxive. The ACIP recommends to vaccinate against pneumococcal with one of the following vaccines:
- PCV 15 (Vaxneuvance)
- Prevnar 20
- Capvaxive
Access Vaccines strives to provide members the lowest prices on vaccines recommended by ACIP and supported by the CDC. Access Vaccines members receive discounted pricing on all brands of pneumococcal vaccines. Become an Access Vaccines member today and save on all your pneumococcal purchases.
11.15.24 – CAPVAXIVE Recieves Significant CDC Recommendation
Merck’s pneumococcal conjugate vaccine Capvaxive recently scored a key recommendation from the Centers for Disease Control and Prevention’s (CDC’s) vaccine advisory group to expand its use to all adults aged 50 and older, compared to a previous endorsement for people 65 and older. About 120 million people in the U.S. are over the age of 50, with 60 million between the ages of 50 to 64.
CAPVAXIVE is the only pneumococcal vaccine specifically designed to protect adults 50 and older with 21 serotypes. The 50 and older age range account for 84% of the disease found in that population, according to Merck.
10.30.24 – CDC Updates Recommendations for COVID-19 and Pneumococcal Vaccinations
CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for 2 Groups:
– 65 Years and Older and for People Who are Moderately or Severely Immunocompromised
– Everyone 6 months and older who are moderately or severely immunocompromised
CDC also lowered the age for which it recommends adult pneumococcal vaccination from 65 to 50 years old. Pneumococcal bacteria can cause serious illnesses, including pneumonia, meningitis, and bloodstream infections.
10.25.24 – FDA Approves First Ever RSV Vaccine Indicated for Adults Younger than 50: Abrysvo by Pfizer
The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD). The approval makes the shot the first of its kind for adults who are younger than 50 years old. Among U.S. adults ages 18 to 49, 9.5% have an underlying chronic condition that increases their risk of developing severe disease, Pfizer said. In the 50 to 64 age group, the prevalence of at-risk individuals rises to 24%.
Abrysvo is a vaccine indicated for:
– the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older
– the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV
– pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
10.8.24 – The CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60–74 years who are at increased risk of severe RSV.
Three RSV vaccines are licensed by the U.S. Food and Drug Administration for use in adults ages 60 and older in the United States:
– GSK’s Arexvy
– Moderna’s mResvia
– Pfizer’s Abrysvo
If your patient has already gotten an RSV vaccine, you do not need to get another one at this time. Your patients can get one at any time, but the best time to get vaccinated is in late summer into fall.
9.18.24 – GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK announces administration of its respiratory syncytial virus (RSV) vaccine: Arexvy and Shingles shot: Shingrix – together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
The trial testing the immune response of co-administration of GSK’s blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study.
RSV causes over 177,000 hospitalizations and 14,000 deaths in the United States annually, while over 1 million people develop shingles every year in the country.
7.31.24 – Groundbreaking: Bavarian Nordic begins commercial launch of mpox vaccine Jynneos in US
After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market.
Jynneos, the only FDA-approved mpox vaccine, is now commercially available in the U.S., Bavarian Nordic announced Tuesday. The commercial rollout means that interested individuals can access the shot at local pharmacies and physician offices, in addition to the limited number of clinics designated by health authorities.
The launch builds on Jynneos’ availability through public health channels since an mpox—then known as monkeypox—outbreak in 2022. It also follows a unanimous decision in October from the U.S. CDC’s Advisory Committee on Immunization Practices to recommend Jynneos as a routine vaccination in adults at risk of mpox infection, backing the shot’s use beyond an outbreak.
7.15.24 – CDC Recommends Vaxelis in American Indian and Alaska Native Populations
Invasive Haemophilus influenzae type b (Hib) disease is a rare but serious bacterial infection that disproportionally affects American Indian and Alaska Native infants. Until now, PedvaxHIB was the only Hib vaccine preferentially recommended over other Hib vaccine options for these infants because it provides a protective antibody response after the first dose.
ACIP voted to recommend that Vaxelis be included in the preferential recommendation for American Indian and Alaska Native infants based on the Hib component. New immunogenicity data after the first dose of Vaxelis are available now and supported the recommendation.
4.29.24 – Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
The Access Vaccines Merck Discount Program provides members with the lowest national price on Gardasil. GARDASIL 9 is a vaccine for patients 9 through 45 years of age for the prevention of certain cancers and other diseases caused by 9 types of human papillomavirus (HPV).
According to a CDC model in 2012-2016: In men, oropharyngeal cancer has been the most prevalent HPV-attributable cancer in the US. Certain HPV-related oropharyngeal cancers affect men (~10,500) ~5x more than women (~2,100).
The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Access Vaccines is proud to offer our members the lowest national price on Gardasil. Become a member today and save.
4.15.24 – Access Vaccines Now Offers Discount on GSK and Moderna Vaccines to Independent Pharmacies
Access Vaccines is proud to announce we are now able to provide discounted member pricing to Independent Pharmacies. For the first time in the history of PBG’s, Access Vaccines is now able to offer our services to Independent Pharmacies throughout the nation.
– Member discounts on GSK vaccines including Shingrix and Flu.
– Member discounts on all Moderna vaccines.
Independent Pharmacies can now take advantage of discount member pricing through Access Vaccines. Enroll your location or group in the Access Vaccines Pharmacy Discount Program today to save on your GSK and Moderna vaccine purchases.
4.10.24 – 2024-25 Influenza Vaccines Transitioning to Trivalent Formulation
U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) provided recommendations for the TIV viral strain selection of influenza vaccines, which align with the February 2024 World Health Organization (WHO) annual recommendations.
3.7.24 – Access Vaccines is Proud to Announce our Newest Partnership: Merck Vaccines
Proud to announce our newest partnership with Merck Vaccines. This partnership continues to expand our portfolio, bringing more options and savings to our members on all administered brands.
The Acces Vaccines Merck Discount Program offers qualifying members discounts on Merck Vaccines. The program provides the Lowest National Price on Gardasil, Rotateq and Vaxneuvance (PCV15). Access Vaccines members who join the Merck Discount program will receive discounts on all Merck Vaccines.
Contact Access Vaccines to join the Merck Discount Program and start saving on all your Merck Vaccine purchases today. Merck Discount Program.
10.19.23 – CDC Recommends Pfizer or Sanofi RSV Vaccine to Provide Protection Against Infant RSV
ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32–36 weeks’ gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
8.31.23 – GSK’s RSV Arexvy: RSV Vaccines Remains Effective Against Distinct Viral Variants
GSK’s Arexvy vaccine for respiratory syncytial virus (RSV) — the first to be approved for older adults — can remain effective against a range of variants and produces strong antibody responses against distinct viral strains, according to a new study. The study results, published in the journal Science Translational Medicine, indicate that the vaccine could offer enduring protection against both contemporary RSV and future variants, especially when combined with vaccine adjuvants.